Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes.
Cristina Leal RodríguezBenjamin Skov Kaas-HansenRobert ErikssonJorge Hernansanz BielKirstine G BellingStig Ejdrup AndersenSoren BrunakPublished in: Pharmacoepidemiology and drug safety (2022)
Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and non-steroidal anti-inflammatory drugs - NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4.
Keyphrases
- anti inflammatory drugs
- end stage renal disease
- ejection fraction
- adverse drug
- risk factors
- primary care
- chronic kidney disease
- helicobacter pylori
- palliative care
- healthcare
- peritoneal dialysis
- cardiovascular events
- cardiovascular disease
- venous thromboembolism
- human health
- patient reported outcomes
- climate change
- acute care